Journal article

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

Bart G Jones, Robert E Sealy, Rajeev Rudraraju, Vicki L Traina-Dorge, Brad Finneyfrock, Anthony Cook, Toru Takimoto, Allen Portner, Julia L Hurwitz

VACCINE | ELSEVIER SCI LTD | Published : 2012

Abstract

Respiratory syncytial virus (RSV) is a serious disease of children, responsible for an estimated 160,000 deaths per year worldwide. Despite the ongoing need for global prevention of RSV and decades of research, there remains no licensed vaccine. Sendai virus (SeV) is a mouse parainfluenza virus-type 1 which has been previously shown to confer protection against its human cousin, human parainfluenza virus-type 1 in African green monkeys (AGM). Here is described the study of a RSV vaccine (SeVRSV), produced by reverse genetics technology using SeV as a backbone to carry the full-length gene for RSV F. To test for immunogenicity, efficacy and safety, the vaccine was administered to AGM by intra..

View full abstract

University of Melbourne Researchers

Grants

Awarded by NIH


Awarded by TNPRC NIH NCRR


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Awarded by OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH


Funding Acknowledgements

This study was supported in part by NIH P30 CA21765, P01 A1054955, R01 A1088729, TNPRC NIH NCRR grant P51RR000164 and the American Lebanese Syrian Associated Charities (ALSAC). We thank C. Russell, J. Shenep and J. DeVincenzo for useful discussions and advice. We thank P. Vogel and the Veterinary Pathology Core of the St. Jude Animal Resource Center for necropsy and histopathology